Inmunoterapia en cáncer de vejiga - page 27

•

N= 119

•

Median overall survival was 15.9 months

•

Tumour mutation load associated with

response.

•

Favorable safety profile (fatigue, diarrhoea

and pruritus )

•

Activity regardless PD-L1 status

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,17,18,19,20,21,22,23,24,25,26 28,29,30,31,32,33,34,35,36